Albendazole: a review of anthelmintic efficacy and safety in humans
The DOI matches its Crossref record.
Abstract
This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole's use as an anthelminthic in humans. Cure rates and % egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400mg. Overall cure rates are also presented separately for studies involving only children 2–15 years. Similar tables are also provided for the recommended dose of 400mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and/or spontaneously reported to the company. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just >1%. Albendazole's unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92% for A. duodenale in 23 studies and 75% for N. americanus in 30 studies), A. lumbricoides (95% in 64 studies), T. trichiura (48% in 57 studies), E. vermicularis (98% in 27 studies), S. stercoralis (62% in 19 studies), H. nana (68% in 11 studies), and Taenia spp. (85% in 7 studies). The facts that albendazole is safe and easy to administer, both in treatment of individuals and in treatment of whole communities where it has been given by paramedical and nonmedical personnel, have enabled its use to improve general community health, including the improved nutrition and development of children.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Horton [53] reviewed the CR of human H. nana infection using 400 mg albendazole daily for 3 days in 13 trials from 1981 until March 1998 to be in the range between 28.5% and 100% (av. 69.5%).”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [53]
In the citing paper
“In most trials, the CR at day 14–17 post-treatment ranged from 93.3 to 100% [53].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [53]
In the citing paper
“However, shorter courses, particularly 400 mg single dose, do not appear to produce a significant cure of the disease [53].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [53]
In the citing paper
“The average CR for A. duodenale was higher (91.8%) than that for N. americanus (75.0%), and those for adults and children in A. duodenale were similar, 91.7% and 90.8%, respectively, whereas those for adults and children in N. americanus were 80.9% and 67.0%, respectively [53].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [53]
In the citing paper
“Thereafter, until March 1999, at least 68 articles reported the efficacy of albendazole (400 mg single dose; the recommended dose by WHO [45]) against hookworm infections (A. duodenale or N. americanus), with CR ranging from 33.3 to 100% (av. 77.7%), and ERR from 29.6 to 100% [53].”
From Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update (2021) · cites this paper as [53]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Still being checked.
Cited by
Keiser, J., & Utzinger, J. (2008) · JAMA · doi:10.1001/jama.299.16.1937 · Cited by 798
Editorial: The Global Programme to Eliminate Lymphatic Filariasis
Ottesen, E. A. (2000) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2000.00620.x · Cited by 572
Human Hookworm Infection in the 21st Century
Brooker, S., Bethony, J., & Hotez, P. J. (2004) · Advances in Parasitology · doi:10.1016/s0065-308x(04)58004-1 · Cited by 419
Clinical Management of Cystic Echinococcosis: State of the Art, Problems, and Perspectives
Junghanss, T., da Silva, A. M., Horton, J., Chiodini, P. L., & Brunetti, E. (2008) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2008.79.301 · Cited by 394
Self-citationA review and meta‐analysis of the impact of intestinal worms on child growth and nutrition
Hall, A., Hewitt, G., Tuffrey, V., & De Silva, N. (2008) · Maternal & Child Nutrition · doi:10.1111/j.1740-8709.2007.00127.x · Cited by 367
Metadata
- Authors
- HORTON, J.
- Corresponding author
- HORTON, J.
- ORCID
- HORTON, J.
- Venue
- Parasitology
- Publisher
- Cambridge University Press (CUP)
- Published
- 2000-10
- Volume
- 121
- Issue
- S1
- Pages
- S113-S132
- ISSN
- 0031-1820 (ISSN-L)
- 1469-8161
- OpenAlex
- W2088719505
- Semantic Scholar
- ff75d295240400e27456092af87e3c3c10dac77f
- Cited by
- 386
- References
- 0
- Citations by year
- 2026: 22 · 2025: 17 · 2024: 13 · 2023: 25 · 2022: 28 · 2021: 25 · 2020: 28 · 2019: 17 · 2018: 13 · 2017: 14 · 2016: 17 · 2015: 22 · 2014: 12 · 2013: 15 · 2012: 10
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Parasitology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Parasitology › Parasites and Host Interactions
- Health Sciences › Medicine › Infectious Diseases › Parasitic Diseases Research and Treatment
- Life Sciences › Immunology and Microbiology › Parasitology › Helminth infection and control
- Keywords
- albendazole, anthelmintic efficacy, drug safety, hookworm infection, Necator americanus, Ancylostoma duodenale, Ascaris lumbricoides, Trichuris trichiura, Enterobius vermicularis, Strongyloides stercoralis, Taenia, Hymenolepis nana, cure rate, egg reduction rate, dosing regimen, pediatric parasitic infection, gastrointestinal adverse effects
- MeSH terms
- Adolescent, Adult, Anthelmintics, Child, Clinical Trials as Topic, Female, Humans, Male, Nematode Infections, Albendazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Albendazole: a review of anthelmintic efficacy and safety in humans. https://app.cochat.ai/papers/10.1017/s0031182000007290
- The paper
- HORTON, J. (2000). Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology. https://doi.org/10.1017/s0031182000007290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.